Ultragenyx exercises option to Regenxbio gene therapy

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said it will exercise its option under a 2015 deal to acquire exclusive rights from RegenxBio Inc. (NASDAQ:RGNX) to develop and commercialize a gene therapy to treat cyclin dependent kinase like 5 (CDKL5) deficiency disorder. ...